What is the controversy over the spinal muscular atrophy drug in Keralam? Explained
The Keralam government's initiative to provide Risdiplam, a treatment for Spinal Muscular Atrophy (SMA), has sparked controversy after switching to a less expensive generic version. Parents of affected children are demanding a return to the branded drug due to concerns over its efficacy, especially after a label indicating clinical trial use was found on the generic version. The state plans to address these concerns in upcoming discussions.